Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma.

Autor: Robinson MJ; Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA., Davis EJ; Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA. elizabeth.j.davis@vumc.org.
Jazyk: angličtina
Zdroj: Current treatment options in oncology [Curr Treat Options Oncol] 2024 Nov; Vol. 25 (11), pp. 1366-1373. Date of Electronic Publication: 2024 Oct 17.
DOI: 10.1007/s11864-024-01269-2
Abstrakt: Opinion Statement: Osteosarcoma is the most common primary malignant bone tumor in adolescents and adults. The 5-year survival rate is 65% when localized; however, survival drops dramatically to 10-20% in cases of metastatic disease. Therapy for osteosarcoma saw its first significant advancement in the 1970-80's, with the introduction of our current standard of care, consisting of the neo/adjuvant treatment regimen methotrexate, doxorubicin (Adriamycin), and cisplatin (collectively referred to as MAP) and surgical resection. Since MAP, development of a better therapeutic approach has stalled, creating a plateau in patient outcomes that has persisted for 40 years. Despite substantial research into a variety of pathways for novel treatment options, clinical trials have not produced sizeable improvements in outcomes. In this article, we discuss our current neoadjuvant standard of care therapy, followed by a review of contemporary therapeutic options, including tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), and chimeric antigen receptor (CAR) T cells. Lastly, we consider the challenges hindering the success of novel treatment options and future research directions.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: